These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

391 related items for PubMed ID: 37821941

  • 1. Prognostic significance of blood-based PD-L1 analysis in patients with non-small cell lung cancer undergoing immune checkpoint inhibitor therapy: a systematic review and meta-analysis.
    Cui Q, Li W, Wang D, Wang S, Yu J.
    World J Surg Oncol; 2023 Oct 11; 21(1):318. PubMed ID: 37821941
    [Abstract] [Full Text] [Related]

  • 2. Prognostic significance of programmed cell death ligand 1 blood markers in non-small cell lung cancer treated with immune checkpoint inhibitors: a systematic review and meta-analysis.
    Zhang N, Chang J, Liu P, Tian X, Yu J.
    Front Immunol; 2024 Oct 11; 15():1400262. PubMed ID: 38915398
    [Abstract] [Full Text] [Related]

  • 3. Prognostic significance of programmed cell death-ligand 1 expression on circulating tumor cells in various cancers: A systematic review and meta-analysis.
    Ouyang Y, Liu W, Zhang N, Yang X, Li J, Long S.
    Cancer Med; 2021 Oct 11; 10(20):7021-7039. PubMed ID: 34423578
    [Abstract] [Full Text] [Related]

  • 4. Association of Survival and Immune-Related Biomarkers With Immunotherapy in Patients With Non-Small Cell Lung Cancer: A Meta-analysis and Individual Patient-Level Analysis.
    Yu Y, Zeng D, Ou Q, Liu S, Li A, Chen Y, Lin D, Gao Q, Zhou H, Liao W, Yao H.
    JAMA Netw Open; 2019 Jul 03; 2(7):e196879. PubMed ID: 31290993
    [Abstract] [Full Text] [Related]

  • 5. Soluble PD-L1 as a Prognostic Factor for Immunotherapy Treatment in Solid Tumors: Systematic Review and Meta-Analysis.
    Scirocchi F, Strigari L, Di Filippo A, Napoletano C, Pace A, Rahimi H, Botticelli A, Rughetti A, Nuti M, Zizzari IG.
    Int J Mol Sci; 2022 Nov 21; 23(22):. PubMed ID: 36430974
    [Abstract] [Full Text] [Related]

  • 6. Soluble PD-L1 as a predictive biomarker in lung cancer: a systematic review and meta-analysis.
    Cheng Y, Wang C, Wang Y, Dai L.
    Future Oncol; 2022 Jan 21; 18(2):261-273. PubMed ID: 34874185
    [Abstract] [Full Text] [Related]

  • 7. Pre-treatment soluble PD-L1 as a predictor of overall survival for immune checkpoint inhibitor therapy: a systematic review and meta-analysis.
    Széles Á, Fazekas T, Váncsa S, Váradi M, Kovács PT, Krafft U, Grünwald V, Hadaschik B, Csizmarik A, Hegyi P, Váradi A, Nyirády P, Szarvas T.
    Cancer Immunol Immunother; 2023 May 21; 72(5):1061-1073. PubMed ID: 36385210
    [Abstract] [Full Text] [Related]

  • 8. Soluble PD-L1 changes in advanced non-small cell lung cancer patients treated with PD-1 inhibitors: an individual patient data meta-analysis.
    Shimizu T, Inoue E, Ohkuma R, Kobayashi S, Tsunoda T, Wada S.
    Front Immunol; 2023 May 21; 14():1308381. PubMed ID: 38115995
    [Abstract] [Full Text] [Related]

  • 9. Safety and Efficacy of PD-1/PD-L1 inhibitors combined with radiotherapy in patients with non-small-cell lung cancer: a systematic review and meta-analysis.
    Geng Y, Zhang Q, Feng S, Li C, Wang L, Zhao X, Yang Z, Li Z, Luo H, Liu R, Lu B, Wang X.
    Cancer Med; 2021 Feb 21; 10(4):1222-1239. PubMed ID: 33465302
    [Abstract] [Full Text] [Related]

  • 10. Efficacy of PD-1/PD-L1 Inhibitors versus Chemotherapy in Lung Cancer with Brain Metastases: A Systematic Review and Meta-Analysis.
    Yang X, Zeng Y, Tan Q, Huang Z, Jia J, Jiang G.
    J Immunol Res; 2022 Feb 21; 2022():4518898. PubMed ID: 35637793
    [Abstract] [Full Text] [Related]

  • 11. Novel Biomarkers of Dynamic Blood PD-L1 Expression for Immune Checkpoint Inhibitors in Advanced Non-Small-Cell Lung Cancer Patients.
    Yang Q, Chen M, Gu J, Niu K, Zhao X, Zheng L, Xu Z, Yu Y, Li F, Meng L, Chen Z, Zhuo W, Zhang L, Sun J.
    Front Immunol; 2021 Feb 21; 12():665133. PubMed ID: 33936103
    [Abstract] [Full Text] [Related]

  • 12. Predictive effect of PD-L1 expression for immune checkpoint inhibitor (PD-1/PD-L1 inhibitors) treatment for non-small cell lung cancer: A meta-analysis.
    Zhang B, Liu Y, Zhou S, Jiang H, Zhu K, Wang R.
    Int Immunopharmacol; 2020 Mar 21; 80():106214. PubMed ID: 31982822
    [Abstract] [Full Text] [Related]

  • 13. Prognostic value of systemic inflammation response index in cancer patients treated with PD-1/PD-L1 immune checkpoint inhibitors: a meta-analysis.
    Gu X, Han X, Shen Y, Shi Y.
    Ann Med; 2024 Dec 21; 56(1):2413415. PubMed ID: 39383059
    [Abstract] [Full Text] [Related]

  • 14. The relationship between blood-based tumor mutation burden level and efficacy of PD-1/PD-L1 inhibitors in advanced non-small cell lung cancer: a systematic review and meta-analysis.
    Ba H, Liu L, Peng Q, Chen J, Zhu YD.
    BMC Cancer; 2021 Nov 13; 21(1):1220. PubMed ID: 34774004
    [Abstract] [Full Text] [Related]

  • 15. Clinical roles of soluble PD-1 and PD-L1 in plasma of NSCLC patients treated with immune checkpoint inhibitors.
    Himuro H, Nakahara Y, Igarashi Y, Kouro T, Higashijima N, Matsuo N, Murakami S, Wei F, Horaguchi S, Tsuji K, Mano Y, Saito H, Azuma K, Sasada T.
    Cancer Immunol Immunother; 2023 Aug 13; 72(8):2829-2840. PubMed ID: 37188764
    [Abstract] [Full Text] [Related]

  • 16. The impact of high PD-L1 expression on the surrogate endpoints and clinical outcomes of anti-PD-1/PD-L1 antibodies in non-small cell lung cancer.
    Ito K, Miura S, Sakaguchi T, Murotani K, Horita N, Akamatsu H, Uemura K, Morita S, Yamamoto N.
    Lung Cancer; 2019 Feb 13; 128():113-119. PubMed ID: 30642442
    [Abstract] [Full Text] [Related]

  • 17. Association between CD8+ tumor-infiltrating lymphocytes and prognosis of non-small cell lung cancer patients treated with PD-1/PD-L1 inhibitors: a systematic review and meta-analysis.
    Zheng QM, Li YY, Wang YP, Li GX, Zhao MM, Sun ZG.
    Expert Rev Anticancer Ther; 2023 Jun 13; 23(6):643-659. PubMed ID: 37114477
    [Abstract] [Full Text] [Related]

  • 18. The efficacy and safety of anti-PD-1/PD-L1 in treatment of glioma: a single-arm meta-analysis.
    Zeng YF, Wei XY, Guo QH, Chen SY, Deng S, Liu ZZ, Gong ZC, Zeng WJ.
    Front Immunol; 2023 Jun 13; 14():1168244. PubMed ID: 37122727
    [Abstract] [Full Text] [Related]

  • 19. Meta-Analysis of Circulating Tumor Cell PD-L1 Expression and the Association with Clinical Outcomes in Non-Small Cell Lung Cancer.
    Acheampong E, Allsopp RC, Page K, Wadsley MK, Beasley AB, Coombes RC, Shaw JA, Gray ES.
    Clin Chem; 2024 Jan 04; 70(1):234-249. PubMed ID: 38175603
    [Abstract] [Full Text] [Related]

  • 20. Biomarkers predicting clinical outcomes in nasopharyngeal cancer patients receiving immune checkpoint inhibitors: A systematic review and meta-analysis.
    Qian X, Chen H, Tao Y.
    Front Immunol; 2023 Jan 04; 14():1146898. PubMed ID: 37063822
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 20.